


WHAT IS CLAIMED IS:


1. A compound of the formula:






and the pharmaceutically acceptable salts and solvates thereof, wherein:



A is selected from the group consisting of:

(1)







5




10







5




(2)



15



5




10

wherein the above rings of said A groups are substituted with 1 to 6 substituents each independently selected from the group consisting of:  $R^9$  groups;


15

(3)



- 10 wherein one or both of the above rings of said A groups are substituted with 1 to 6 substituents each independently selected from the group consisting of:  $R^9$  groups;



(4)





wherein the above phenyl rings of said A groups are substituted with 1 to 3 substituents each independently selected from the group consisting of:  $R^9$  groups; and

5

(5)




10




15

B is selected from the group consisting of:

(1)




provided that  $R^3$  for this group is selected from the group consisting of:  $-C(O)NR^{13}R^{14}$ ,




5

(2)




(3)




10


(4)




(5)




(6)




(7)




(8)



(9)




(10)






(11)




(12)




5

(13)




10

(14)




(15)




15


(16)



(17)



(18)




- 10        n is 0 to 6;  
           p is 1 to 5;  
           X is O, NH, or S;  
           Z is 1 to 3;

15         $R^2$  is selected from the group consisting of: hydrogen, OH, -C(O)OH, -SH, -SO<sub>2</sub>NR<sup>13</sup>R<sup>14</sup>, -NHC(O)R<sup>13</sup>, -NHSO<sub>2</sub>NR<sup>13</sup>R<sup>14</sup>, -NHSO<sub>2</sub>R<sup>13</sup>, -NR<sup>13</sup>R<sup>14</sup>, -C(O)NR<sup>13</sup>R<sup>14</sup>, -C(O)NHO<sup>13</sup>, -C(O)NR<sup>13</sup>OH, -S(O<sub>2</sub>)OH, -OC(O)R<sup>13</sup>, an unsubstituted heterocyclic acidic functional group, and a substituted heterocyclic acidic functional group; wherein there are 1 to 6 substituents on said substituted heterocyclic acidic functional group each substituent being independently selected from the group consisting of: R<sup>9</sup> groups;

20

          each R<sup>3</sup> and R<sup>4</sup> is independently selected from the group consisting of: hydrogen, cyano, halogen, alkyl, alkoxy, -OH, -CF<sub>3</sub>, -OCF<sub>3</sub>, -NO<sub>2</sub>, -C(O)R<sup>13</sup>,

$-\text{C}(\text{O})\text{OR}^{13}$ ,  $-\text{C}(\text{O})\text{NHR}^{17}$ ,  $-\text{C}(\text{O})\text{NR}^{13}\text{R}^{14}$ ,  $-\text{SO}_{(t)}\text{NR}^{13}\text{R}^{14}$ ,  $-\text{SO}_{(t)}\text{R}^{13}$ ,  $-\text{C}(\text{O})\text{NR}^{13}\text{OR}^{14}$ , unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl,



wherein there are 1 to 6 substituents on said substituted aryl group and each

5 substituent is independently selected from the group consisting of: R<sup>9</sup> groups; and

wherein there are 1 to 6 substituents on said substituted heteroaryl group and each substituent is independently selected from the group consisting of: R<sup>9</sup> groups;

each R<sup>5</sup> and R<sup>6</sup> are the same or different and are independently selected from the group consisting of hydrogen, halogen, alkyl, alkoxy,  $-\text{CF}_3$ ,  $-\text{OCF}_3$ ,

10  $-\text{NO}_2$ ,  $-\text{C}(\text{O})\text{R}^{13}$ ,  $-\text{C}(\text{O})\text{OR}^{13}$ ,  $-\text{C}(\text{O})\text{NR}^{13}\text{R}^{14}$ ,  $-\text{SO}_{(t)}\text{NR}^{13}\text{R}^{14}$ ,  $-\text{C}(\text{O})\text{NR}^{13}\text{OR}^{14}$ , cyano, unsubstituted or substituted aryl, and unsubstituted or substituted heteroaryl group;

wherein there are 1 to 6 substituents on said substituted aryl group and each

substituent is independently selected from the group consisting of: R<sup>9</sup> groups; and

wherein there are 1 to 6 substituents on said substituted heteroaryl group and each

15 substituent is independently selected from the group consisting of: R<sup>9</sup> groups;

each R<sup>7</sup> and R<sup>8</sup> is independently selected from the group consisting of: H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heteroarylalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted cycloalkylalkyl,  $-\text{CO}_2\text{R}^{13}$ ,  $-\text{CONR}^{13}\text{R}^{14}$ , alkynyl, alkenyl, and cycloalkenyl;

20 and wherein there are one or more substituents on said substituted R<sup>7</sup> and R<sup>8</sup> groups, wherein each substituent is independently selected from the group consisting of:


- a) halogen,
- b)  $-\text{CF}_3$ ,
- 25 c)  $-\text{COR}^{13}$ ,
- d)  $-\text{OR}^{13}$ ,
- e)  $-\text{NR}^{13}\text{R}^{14}$ ,
- f)  $-\text{NO}_2$ ,
- g)  $-\text{CN}$ ,
- 30 h)  $-\text{SO}_2\text{OR}^{13}$ ,

- i)  $-\text{Si}(\text{alkyl})_3$ , wherein each alkyl is independently selected,  
 j)  $-\text{Si}(\text{aryl})_3$ , wherein each alkyl is independently selected,  
 k)  $-(\text{R}^{13})_2\text{R}^{14}\text{Si}$ , wherein each  $\text{R}^{13}$  is independently selected,  
 l)  $-\text{CO}_2\text{R}^{13}$ ,  
 5 m)  $-\text{C}(\text{O})\text{NR}^{13}\text{R}^{14}$ ,  
 n)  $-\text{SO}_2\text{NR}^{13}\text{R}^{14}$ ,  
 o)  $-\text{SO}_2\text{R}^{13}$ ,  
 p)  $-\text{OC}(\text{O})\text{R}^{13}$ ,  
 q)  $-\text{OC}(\text{O})\text{NR}^{13}\text{R}^{14}$ ,  
 10 r)  $-\text{NR}^{13}\text{C}(\text{O})\text{R}^{14}$ , and  
 s)  $-\text{NR}^{13}\text{CO}_2\text{R}^{14}$ ;

$\text{R}^{8a}$  is selected from the group consisting of: hydrogen, alkyl, cycloalkyl and cycloalkylalkyl;

each  $\text{R}^9$  is independently selected from the group consisting of:

- 15 a)  $-\text{R}^{13}$ ,  
 b) halogen,  
 c)  $-\text{CF}_3$ ,  
 d)  $-\text{COR}^{13}$ ,  
 e)  $-\text{OR}^{13}$ ,  
 20 f)  $-\text{NR}^{13}\text{R}^{14}$ ,  
 g)  $-\text{NO}_2$ ,  
 h)  $-\text{CN}$ ,  
 i)  $-\text{SO}_2\text{R}^{13}$ ,  
 j)  $-\text{SO}_2\text{NR}^{13}\text{R}^{14}$ ,  
 25 k)  $-\text{NR}^{13}\text{COR}^{14}$ ,  
 l)  $-\text{CONR}^{13}\text{R}^{14}$ ,  
 m)  $-\text{NR}^{13}\text{CO}_2\text{R}^{14}$ ,  
 n)  $-\text{CO}_2\text{R}^{13}$ ,  
 o)



- p) alkyl substituted with one or more  $\text{-OH}$  groups,
- q) alkyl substituted with one or more  $\text{-NR}^{13}\text{R}^{14}$  group, and
- r)  $\text{-N(R}^{13})\text{SO}_2\text{R}^{14}$ ;

each  $\text{R}^{10}$  and  $\text{R}^{11}$  is independently selected from the group consisting of  $\text{R}^{13}$ ,  
 5 hydrogen, alkyl (e.g.,  $\text{C}_1$  to  $\text{C}_6$ , such as methyl), halogen,  $\text{-CF}_3$ ,  $\text{-OCF}_3$ ,  $\text{-NR}^{13}\text{R}^{14}$ ,  
 $\text{-NR}^{13}\text{C(O)NR}^{13}\text{R}^{14}$ ,  $\text{-OH}$ ,  $\text{-C(O)OR}^{13}$ ,  $\text{-SH}$ ,  $\text{-SO}_{(t)}\text{NR}^{13}\text{R}^{14}$ ,  $\text{-SO}_2\text{R}^{13}$ ,  $\text{-NHC(O)R}^{13}$ ,  
 $\text{-NHSO}_2\text{NR}^{13}\text{R}^{14}$ ,  $\text{-NHSO}_2\text{R}^{13}$ ,  $\text{-C(O)NR}^{13}\text{R}^{14}$ ,  $\text{-C(O)NR}^{13}\text{OR}^{14}$ ,  $\text{-OC(O)R}^{13}$  and cyano;

$\text{R}^{12}$  is selected from the group consisting of: hydrogen,  $\text{-C(O)OR}^{13}$ ,  
 unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted  
 10 or substituted arylalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or  
 substituted alkyl, unsubstituted or substituted cycloalkylalkyl, and unsubstituted or  
 substituted heteroarylalkyl group; wherein there are 1 to 6 substituents on the  
 substituted  $\text{R}^{12}$  groups and each substituent is independently selected from the group  
 consisting of:  $\text{R}^9$  groups;

15 each  $\text{R}^{13}$  and  $\text{R}^{14}$  is independently selected from the group consisting of: H,  
 unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or  
 substituted heteroaryl, unsubstituted or substituted arylalkyl, unsubstituted or  
 substituted heteroarylalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or  
 substituted cycloalkylalkyl, unsubstituted or substituted heterocyclic, unsubstituted or  
 20 substituted fluoroalkyl, and unsubstituted or substituted heterocycloalkylalkyl (wherein  
 "heterocycloalkyl" means heterocyclic); wherein there are 1 to 6 substituents on said  
 substituted  $\text{R}^{13}$  and  $\text{R}^{14}$  groups and each substituent is independently selected from  
 the group consisting of: alkyl,  $\text{-CF}_3$ ,  $\text{-OH}$ , alkoxy, aryl, arylalkyl, fluoroalkyl, cycloalkyl,  
 cycloalkylalkyl, heteroaryl, heteroarylalkyl,  $\text{-N(R}^{40})_2$ ,  $\text{-C(O)OR}^{15}$ ,  $\text{-C(O)NR}^{15}\text{R}^{16}$ ,  
 25  $\text{-S(O)}_t\text{NR}^{15}\text{R}^{16}$ ,  $\text{-C(O)R}^{15}$ ,  $\text{-SO}_2\text{R}^{15}$  provided that  $\text{R}^{15}$  is not H, halogen, and  
 $\text{-NHC(O)NR}^{15}\text{R}^{16}$ ; or

$\text{R}^{13}$  and  $\text{R}^{14}$  taken together with the nitrogen they are attached to in the groups  
 $\text{-C(O)NR}^{13}\text{R}^{14}$  and  $\text{-SO}_2\text{NR}^{13}\text{R}^{14}$  form an unsubstituted or substituted saturated  
 heterocyclic ring, said ring optionally containing one additional heteroatom selected  
 30 from the group consisting of: O, S and  $\text{NR}^{18}$ ; wherein there are 1 to 3 substituents on  
 the substituted cyclized  $\text{R}^{13}$  and  $\text{R}^{14}$  groups and each substituent is independently  
 selected from the group consisting of: alkyl, aryl, hydroxy, hydroxyalkyl, alkoxy,  
 alkoxyalkyl, arylalkyl, fluoroalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl,

amino,  $-\text{C}(\text{O})\text{OR}^{15}$ ,  $-\text{C}(\text{O})\text{NR}^{15}\text{R}^{16}$ ,  $-\text{SO}_2\text{NR}^{15}\text{R}^{16}$ ,  $-\text{C}(\text{O})\text{R}^{15}$ ,  $-\text{SO}_2\text{R}^{15}$  provided that  $\text{R}^{15}$  is not H,  $-\text{NHC}(\text{O})\text{NR}^{15}\text{R}^{16}$ ,  $-\text{NHC}(\text{O})\text{OR}^{15}$ , halogen, and a heterocycloalkenyl group;

each  $\text{R}^{15}$  and  $\text{R}^{16}$  is independently selected from the group consisting of: H, alkyl, aryl, arylalkyl, cycloalkyl and heteroaryl;

$\text{R}^{17}$  is selected from the group consisting of:  $-\text{SO}_2\text{alkyl}$ ,  $-\text{SO}_2\text{aryl}$ ,  $-\text{SO}_2\text{cycloalkyl}$ , and  $-\text{SO}_2\text{heteroaryl}$ ;

$\text{R}^{18}$  is selected from the group consisting of: H, alkyl, aryl, heteroaryl,  $-\text{C}(\text{O})\text{R}^{19}$ ,  $-\text{SO}_2\text{R}^{19}$  and  $-\text{C}(\text{O})\text{NR}^{19}\text{R}^{20}$ ;

each  $\text{R}^{19}$  and  $\text{R}^{20}$  is independently selected from the group consisting of: alkyl, aryl and heteroaryl;

$\text{R}^{30}$  is selected from the group consisting of: alkyl, cycloalkyl,  $-\text{CN}$ ,  $-\text{NO}_2$ , or  $-\text{SO}_2\text{R}^{15}$  provided that  $\text{R}^{15}$  is not H;


each  $\text{R}^{31}$  is independently selected from the group consisting of: unsubstituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl and unsubstituted or substituted cycloalkyl; wherein there are 1 to 6 substituents on said substituted  $\text{R}^{31}$  groups and each substituent is independently selected from the group consisting of: alkyl, halogen and  $-\text{CF}_3$ ;

each  $\text{R}^{40}$  is independently selected from the group consisting of: H, alkyl and cycloalkyl; and


$t$  is 0, 1 or 2.

2. The compound of Claim 1 wherein B is selected from the group consisting of:


(1)



provided that  $\text{R}^3$  for this group is selected from the group consisting of:  $-\text{C}(\text{O})\text{NR}^{13}\text{R}^{14}$ ,




(2)




5

(3)




(4)




10

(5)




15

(6)




(7)




5


3. The compound of Claim 1 wherein B is:



10 wherein R<sup>3</sup> is selected from the group consisting of:  $-\text{C}(\text{O})\text{NR}^{13}\text{R}^{14}$ ,




4. The compound of Claim 1 wherein B is:



15




5. The compound of Claim 1 wherein B is:




$R^2$  is  $-OH$ , and  $R^{13}$  and  $R^{14}$  are each the same or different alkyl group.

5

6. The compound of Claim 1 wherein B is




$R^3$  is selected from the group consisting of:



10


7. The compound of Claim 1 wherein B is:



and  $R^2$  is  $-OH$ .

15


8. The compound of Claim 1 wherein B is



$R^{13}$  and  $R^{14}$  are each the same or different alkyl group.

5

9. The compound of Claim 1 wherein B is



10

10. The compound of Claim 9 wherein  $R^2$  is  $-OH$ .

11. The compound of Claim 9 wherein  $R^{13}$  and  $R^{14}$  are the same or different alkyl group.

15

12. The compound of Claim 11 wherein the  $R^2$  substituent is  $-OH$ .


13. The compound of Claim 11 wherein  $R^{13}$  and  $R^{14}$  methyl.

20

14. The compound of Claim 13 wherein the  $R^2$  substituent is  $-OH$ .


25

15. The compound of Claim 1 wherein B is selected from the group consisting of:



5

16. The compound of Claim 1 wherein B is



10

17. The compound of Claim 16 wherein  $R^{11}$  is H.

15

18. The compound of Claim 16 wherein  $R^2$  is  $-OH$ .

19. The compound of Claim 16 wherein  $R^3$  is  $-C(O)NR^{13}R^{14}$ .

20

20. The compound of Claim 16 wherein  $R^2$  is  $-OH$  and  $R^3$  is  $-C(O)NR^{13}R^{14}$ .

21. The compound of Claim 16 wherein  $R^2$  is  $-OH$ ,  $R^3$  is  $-C(O)NR^{13}R^{14}$ , and  $R^{11}$  is H.

22. The compound of Claim 21 wherein  $R^{13}$  and  $R^{14}$  are each independently selected from the group consisting of: alkyl, unsubstituted heteroaryl and substituted heteroaryl.

23. The compound of Claim 16 wherein  $R^3$  is  $-S(O)_tNR^{13}R^{14}$ .


24. The compound of Claim 23 wherein  $R^2$  is  $-OH$ .

25. The compound of Claim 24 wherein the  $R^{13}$  and  $R^{14}$  substituents are the same or different and are selected from the group consisting of: H and alkyl.


26. The compound of Claim 25 wherein each  $R^{13}$  and  $R^{14}$  are independently selected from the group consisting of: H, methyl, ethyl, isopropyl and t-butyl.

27. The compound of Claim 26 wherein  $R^{13}$  and  $R^{14}$  are ethyl.


28. The compound of Claim 1 wherein B is



29. The compound of Claim 1 wherein B is




5 30. The compound of Claim 1 wherein A is




wherein the furan ring is unsubstituted or substituted.

10 31. The compound of Claim 1 wherein A is



wherein the furan ring is substituted.

15 32. The compound of Claim 1 wherein A is



wherein the furan ring is substituted with at least one alkyl group.

20 33. The compound of Claim 30 wherein R⁷ and R⁸ are independently selected from the group consisting of: H and alkyl.


34. The compound of Claim 33 wherein  $R^7$  is H, and  $R^8$  is alkyl.

35. The compound of Claim 32 wherein  $R^7$  and  $R^8$  are independently  
5 selected from the group consisting of: H and alkyl.


36. The compound of Claim 35 wherein  $R^7$  is H, and  $R^8$  is alkyl.

37. The compound of Claim 1 wherein A is selected from the group  
10 consisting of:

(a)




15



wherein the above rings are unsubstituted, or the above rings are substituted with 1 to  
3 substituents independently selected from the group consisting of: H, F, Cl, Br, alkyl,  
cycloalkyl, and  $-\text{CF}_3$ ;  $R^7$  is selected from the group consisting of: H,  $-\text{CF}_3$ ,  $-\text{CF}_2\text{CH}_3$ ,  
20 methyl, ethyl, isopropyl, cyclopropyl and t-butyl; and  $R^8$  is H; and


(b)



wherein  $R^7$  is selected from the group consisting of: H,  $-\text{CF}_3$ ,  $-\text{CF}_2\text{CH}_3$ , methyl, ethyl,  
isopropyl, cyclopropyl and t-butyl; and  $R^8$  is H; and  $R^{8a}$  is as defined for formula IA.

25


38. The compound of Claim 4 wherein A is



wherein the furan ring is unsubstituted or substituted.

5

39. The compound of Claim 4 wherein A is



wherein the furan ring is substituted with at least one alkyl group.


10

40. The compound of Claim 39 wherein  $R^7$  and  $R^8$  are independently selected from the group consisting of: H and alkyl.

15

41. The compound of Claim 40 wherein  $R^7$  is H and  $R^8$  is alkyl.


42. The compound of Claim 5 wherein A is



20

wherein the furan ring is unsubstituted or substituted.

43. The compound of Claim 42 wherein A is




25

wherein the furan ring is substituted with at least one alkyl group.

44. The compound of Claim 43 wherein  $R^7$  and  $R^8$  are independently selected from the group consisting of: H and alkyl.


45. The compound of Claim 44 wherein  $R^7$  is H and  $R^8$  is alkyl.

46. The compound of Claim 9 wherein A is



wherein the furan ring is unsubstituted or substituted.

47. The compound of Claim 9 wherein A is




wherein the furan ring is substituted with at least one alkyl group.

48. The compound of Claim 47 wherein  $R^7$  and  $R^8$  are independently selected from the group consisting of: H and alkyl.

49. The compound of Claim 48 wherein  $R^7$  is H and  $R^8$  is alkyl.


50. The compound of Claim 10 wherein A is



wherein the furan ring is unsubstituted or substituted.



51. The compound of Claim 10 wherein A is



wherein the furan ring is substituted with at least one alkyl group.


5

52. The compound of Claim 51 wherein R<sup>7</sup> and R<sup>8</sup> are independently selected from the group consisting of: H and alkyl.

10

53. The compound of Claim 52 wherein R<sup>7</sup> is H and R<sup>8</sup> is alkyl.


54. The compound of Claim 12 wherein A is



15

wherein the furan ring is unsubstituted or substituted.

55. The compound of Claim 12 wherein A is



20

wherein the furan ring is substituted with at least one alkyl group.

56. The compound of Claim 55 wherein R<sup>7</sup> and R<sup>8</sup> are independently selected from the group consisting of: H and alkyl.



25

57. The compound of Claim 56 wherein R<sup>7</sup> is H and R<sup>8</sup> is alkyl.

58. The compound of Claim 1 wherein:


(1) A is selected from the group consisting of:

(a)




wherein the above rings are unsubstituted, or the above rings are substituted with 1 to 3 substituents independently selected from the group consisting of: F, Cl, Br, alkyl, cycloalkyl, and  $-\text{CF}_3$ ;  $\text{R}^7$  is selected from the group consisting of: H,  $-\text{CF}_3$ ,  $-\text{CF}_2\text{CH}_3$ , methyl, ethyl, isopropyl, cyclopropyl and t-butyl; and  $\text{R}^8$  is H; and

(b)



wherein  $\text{R}^7$  is selected from the group consisting of: H,  $-\text{CF}_3$ ,  $-\text{CF}_2\text{CH}_3$ , methyl, ethyl, isopropyl, cyclopropyl and t-butyl; and  $\text{R}^8$  is H; and  $\text{R}^{8a}$  is as defined for formula IA;

(2) B is:



wherein:

$\text{R}^2$  is selected from the group consisting of: H, OH,  $-\text{NHC}(\text{O})\text{R}^{13}$  and  $-\text{NH}\text{SO}_2\text{R}^{13}$ ;

$\text{R}^4$  is selected from the group consisting of: H,  $-\text{NO}_2$ , cyano,  $-\text{CH}_3$  or  $-\text{CF}_3$ ;

$\text{R}^5$  is selected from the group consisting of: H,  $-\text{CF}_3$ ,  $-\text{NO}_2$ , halogen and cyano;

and


$R^6$  is selected from the group consisting of: H, alkyl and  $-CF_3$ ; and each  $R^{13}$  and  $R^{14}$  is independently selected from the group consisting of: methyl and ethyl.

5


59. The compound of Claim 1 wherein:

(1) A is selected from the group consisting of:

(a)




10



wherein the above rings are unsubstituted, or the above rings are substituted with 1 to 3 substituents independently selected from the group consisting of: F, Cl, Br, alkyl, cycloalkyl, and  $-CF_3$ ;  $R^7$  is selected from the group consisting of: H,  $-CF_3$ ,  $-CF_2CH_3$ , methyl, ethyl, isopropyl, cyclopropyl and t-butyl; and  $R^8$  is H; and

15


(b)



wherein  $R^7$  is selected from the group consisting of: H,  $-CF_3$ ,  $-CF_2CH_3$ , methyl, ethyl, isopropyl, cyclopropyl and t-butyl; and  $R^8$  is H; and  $R^{8a}$  is as defined for formula IA;

20

(2) B is selected:



wherein:

$R^2$  is selected from the group consisting of: H, OH,  $-NHC(O)R^{13}$  and  $-NHSO_2R^{13}$ ;

$R^3$  is selected from the group consisting of:  $-C(O)NR^{13}R^{14}$ ,  $-SO_2NR^{13}R^{14}$ ,  $-NO_2$ , cyano, and  $-SO_2R^{13}$ ;


$R^{11}$  is selected from the group consisting of: H, halogen and alkyl; and

each  $R^{13}$  and  $R^{14}$  is independently selected from the group consisting of: H, methyl, ethyl, isopropyl, and t-butyl.

60. The compound of Claim 1 wherein:


(1) A is selected from the group consisting of:

(a)




wherein the above rings are unsubstituted, or the above rings are substituted with 1 to 3 substituents independently selected from the group consisting of: F, Cl, Br, alkyl, cycloalkyl, and  $-CF_3$ ;  $R^7$  is selected from the group consisting of: H,  $-CF_3$ ,  $-CF_2CH_3$ , methyl, ethyl, isopropyl, cyclopropyl and t-butyl; and  $R^8$  is H; and

(b)



wherein  $R^7$  is selected from the group consisting of: H,  $-CF_3$ ,  $-CF_2CH_3$ , methyl, ethyl, isopropyl, cyclopropyl and t-butyl; and  $R^8$  is H; and  $R^{8a}$  is as defined for formula IA;

(2) B is selected:



wherein:

$R^2$  is selected from the group consisting of: H, OH,  $-NHC(O)R^{13}$  and  $-NHSO_2R^{13}$ ;

$R^3$  is  $-SO_2NR^{13}R^{14}$ ;


$R^{11}$  is selected from the group consisting of: H, halogen and alkyl; and

each  $R^{13}$  and  $R^{14}$  is independently selected from the group consisting of: H, methyl, ethyl, isopropyl, and t-butyl.

61. The compound of Claim 1 wherein:


(1) A is selected from the group consisting of:

(a)




wherein the above rings are unsubstituted, or the above rings are substituted with 1 to 3 substituents independently selected from the group consisting of: F, Cl, Br, alkyl, cycloalkyl, and  $-CF_3$ ;  $R^7$  is selected from the group consisting of: H,  $-CF_3$ ,  $-CF_2CH_3$ , methyl, ethyl, isopropyl, cyclopropyl and t-butyl; and  $R^8$  is H; and

(b)



wherein  $R^7$  is selected from the group consisting of: H,  $-CF_3$ ,  $-CF_2CH_3$ , methyl, ethyl, isopropyl, cyclopropyl and t-butyl; and  $R^8$  is H; and  $R^{8a}$  is as defined for formula IA;

(2) B is selected:



wherein:

$R^2$  is selected from the group consisting of: H, OH,  $-NHC(O)R^{13}$  and  $-NHSO_2R^{13}$ ;


$R^3$  is  $-SO_2NR^{13}R^{14}$ ;


$R^{11}$  is selected from the group consisting of: H, halogen and alkyl; and each  $R^{13}$  and  $R^{14}$  is ethyl.

5


62. The compound of Claim 1 wherein

(1) A is selected from the group consisting of:





(2) B is:



wherein:

$R^2$  is  $-OH$ ;

$R^4$  is selected from the group consisting of: H,  $-CH_3$  and  $-CF_3$ ;


$R^5$  is selected from the group consisting of: H and cyano;

5  $R^6$  is selected from the group consisting of: H,  $-CH_3$  and  $-CF_3$ ;


$R^{13}$  and  $R^{14}$  are methyl.

63. The compound of Claim 1 wherein


10 (1) A is selected from the group consisting of:







(2) B is:



wherein:

$R^2$  is  $-OH$ ;


$R^3$  is selected from the group consisting of:  $-SO_2NR^{13}R^{14}$  and  $-CONR^{13}R^{14}$ ;


$R^{11}$  is H; and

each  $R^{13}$  and  $R^{14}$  are independently selected from the group consisting of: H,  
5 methyl, ethyl, isopropyl and t-butyl.


64. The compound of Claim 1 wherein

(1) A is selected from the group consisting of:





(2) B is:



wherein:

$R^2$  is  $-OH$ ;

$R^3$  is  $-\text{SO}_2\text{NR}^{13}\text{R}^{14}$ ;


$R^{11}$  is H; and


each  $R^{13}$  and  $R^{14}$  are independently selected from the group consisting of: H, methyl, ethyl, isopropyl and t-butyl.

5


65. The compound of Claim 1 wherein

(1) A is selected from the group consisting of:





(2) B is:



wherein:

R<sup>2</sup> is -OH;

$R^3$  is  $-\text{SO}_2\text{NR}^{13}\text{R}^{14}$ ;

$R^{11}$  is H; and

$R^{13}$  and  $R^{14}$  are ethyl.


















5















66. The compound of Claim 1 wherein said compound is a calcium salt.

67. The compound of Claim 1 wherein said compound is a sodium salt.















10















68. The compound of Claim 1 wherein said compound is selected from the group consisting of:









































































































5




10

































and





69. The compound of Claim 1 selected from the group consisting of:






















5




10


















70. The compound of Claim 1 selected from the group consisting of:











5





10




5














10







71. The compound of Claim 1 selected from the group consisting of:








5



10






5

72. The compound of Claim 71 wherein said compound is a calcium or sodium salt.

10


73. The compound of Claim 1 wherein said compound is:



or a pharmaceutically acceptable salt or solvate thereof.


15

74. The compound of Claim 1 wherein said compound is:



or a pharmaceutically acceptable salt or solvate thereof.


75. The compound of Claim 1 wherein said compound is:



or a pharmaceutically acceptable salt or solvate thereof.

5


76. The compound of Claim 1 wherein said compound is:



or a pharmaceutically acceptable salt or solvate thereof.

10


77. The compound of Claim 1 wherein said compound is:



or a pharmaceutically acceptable salt or solvate thereof.

15


78. The compound of Claim 1 wherein said compound is:



or a pharmaceutically acceptable salt or solvate thereof.

79. The compound of Claim 1 wherein said compound is:


5



or a pharmaceutically acceptable salt or solvate thereof.

80. The compound of Claim 1 wherein said compound is:


10



or a pharmaceutically acceptable salt or solvate thereof.

15

81. The compound of Claim 1 wherein said compound is:




20

or a pharmaceutically acceptable salt or solvate thereof.




10




15

20




or a pharmaceutically acceptable salt or solvate thereof.

20



or a pharmaceutically acceptable salt or solvate thereof.


85. The compound of Claim 1 wherein said compound is:



or a pharmaceutically acceptable salt or solvate thereof.

5


86. The compound of Claim 1 wherein said compound is:



or a pharmaceutically acceptable salt or solvate thereof.

10


87. The compound of Claim 1 wherein said compound is:



or a pharmaceutically acceptable salt or solvate thereof.

15


88. The compound of Claim 1 wherein said compound is:



or a pharmaceutically acceptable salt or solvate thereof.


5

89. The compound of Claim 1 wherein said compound is:



10 or a pharmaceutically acceptable salt or solvate thereof.

90. The compound of Claim 1 wherein said compound is:




15

or a pharmaceutically acceptable salt or solvate thereof.

91. The compound of Claim 1 wherein said compound is:


20

494




or a pharmaceutically acceptable salt or solvate thereof.

5 93. The compound of Claim 1 wherein said compound is:




or a pharmaceutically acceptable salt or solvate thereof.

10 94. The compound of Claim 1 wherein said compound is:



or a pharmaceutically acceptable salt or solvate thereof.

15 95. The compound of claim 1 wherein said compound is:



20 or a pharmaceutically acceptable salt or solvate thereof.

96. The compound of Claim 1 selected from the group consisting of the final compounds of Examples 1 to 2088.

5 97. The compound of Claim 96 wherein said compound is a calcium or sodium salt of a final compound of Examples 1 to 2088.

10 98. The compound of Claim 1 selected from the group consisting of the final compounds of Examples 2006, 2010, 2015, 2029, 2034, 2035, 2038, 2039, 2047, 2050, 2074, 2079 and 2087.

15 99. The compound of Claim 98 wherein said compound is a calcium or sodium salt of a final compound of Examples 2006, 2010, 2015, 2029, 2034, 2035, 2038, 2039, 2047, 2050, 2074, 2079 and 2087.

20 100. The compound of Claim 83 wherein said compound is a calcium or sodium salt.

25 101. The compound of Claim 84 wherein said compound is a calcium or sodium salt.

102. The compound of Claim 85 wherein said compound is a calcium or sodium salt.

30 103. A pharmaceutical composition comprising an effective amount of a compound of Claim 1 in combination with a pharmaceutically acceptable carrier.

104. A method of treating a chemokine-mediated disease, in a patient in need of such treatment, wherein the chemokine binds to a CXCR2 and/or CXCR1 receptor in said patient, comprising administering to said patient an effective amount of at least one compound of Claim 1.

5

105. A method of treating a chemokine-mediated disease, in a patient in need of such treatment, wherein the chemokine binds to a CXC receptor in said patient, comprising administering to said patient an effective amount of at least one compound of Claim 1.

10

106. The method of Claim 104 wherein the chemokine mediated disease is selected from the group consisting of: acute inflammatory pain, chronic inflammatory pain, acute neuropathic pain, chronic neuropathic pain, acute inflammation, rheumatoid arthritis, psoriasis, atopic dermatitis, asthma, COPD, adult respiratory disease, arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, stroke, cardiac and renal reperfusion injury, glomerulonephritis, thrombosis, Alzheimer's disease, graft vs. host reaction, allograft rejections, malaria, acute respiratory distress syndrome, delayed type hypersensitivity reaction, atherosclerosis, cerebral and cardiac ischemia, osteoarthritis, multiple sclerosis, restinosis, angiogenesis, osteoporosis, gingivitis, respiratory viruses, herpes viruses, hepatitis viruses, HIV, Kaposi's sarcoma associated virus, meningitis, cystic fibrosis, pre-term labor, cough, pruritis, multi-organ dysfunction, trauma, strains, sprains, contusions, psoriatic arthritis, herpes, encephalitis, CNS vasculitis, traumatic brain injury, CNS tumors, subarachnoid hemorrhage, post surgical trauma, interstitial pneumonitis, hypersensitivity, crystal induced arthritis, acute and chronic pancreatitis, acute alcoholic hepatitis, necrotizing enterocolitis, chronic sinusitis, angiogenic ocular disease, ocular inflammation, retinopathy of prematurity, diabetic retinopathy, macular degeneration with the wet type preferred and corneal neovascularization, polymyositis, vasculitis, acne, gastric and duodenal ulcers, celiac disease, esophagitis, glossitis, airflow obstruction, airway hyperresponsiveness, bronchiectasis,

15

20

25

30

bronchiolitis, bronchiolitis obliterans, chronic bronchitis, cor pulmonae, cough, dyspnea, emphysema, hypercapnea, hyperinflation, hypoxemia, hyperoxia-induced inflammations, hypoxia, surgical lung volume reduction, pulmonary fibrosis, pulmonary hypertension, right ventricular hypertrophy, peritonitis associated with continuous ambulatory peritoneal dialysis (CAPD), granulocytic ehrlichiosis, sarcoidosis, small airway disease, ventilation-perfusion mismatching, wheeze, colds, gout, alcoholic liver disease, lupus, burn therapy, periodontitis, transplant reperfusion injury and early transplantation rejection, and chronic inflammation.

10            107. A method of treating cancer in a patient in need of such treatment comprising administering to said patient an effective amount of at least one compound of Claim 1.

15            108. A method of treating cancer in a patient in need of such treatment comprising administering to said patient an effective amount of at least one compound of Claim 1 in combination with the administration of at least one anticancer agent.

20            109. The method of Claim 108 wherein said anticancer agent is selected from the group consisting of: alkylating agents, antimetabolites, natural products and their derivatives, hormones, anti-hormones, anti-angiogenic agents and steroids, and synthetics.

25            110. A method of inhibiting angiogenesis in a patient in need of such treatment comprising administering to said patient an effective amount of at least one compound of Claim 1.

30            111. A method of inhibiting angiogenesis in a patient in need of such treatment comprising administering to said patient an effective amount of at least one

compound of Claim 1 in combination with the administration an effective amount of at least one anti-angiogenesis compound.

5           112. A method of treating a disease selected from the group consisting of: gingivitis, respiratory viruses, herpes viruses, hepatitis viruses, HIV, kaposi's sarcoma associated virus and atherosclerosis, in a patient in need of such treatment, comprising administering to said patient an effective amount of at least one compound of Claim 1.

10

          113. The method of Claim 112 wherein the chemokine mediated disease is an angiogenic ocular disease.

15

          114. The method of Claim 113 wherein said angiogenic ocular disease is selected from the group consisting of: ocular inflammation, retinopathy of prematurity, diabetic retinopathy, macular degeneration with the wet type preferred and corneal neovascularization.

20

          115. The method of Claim 107 wherein the cancer treated is melanoma, gastric carcinoma, or non-small cell lung carcinoma.

25

          116. The method of Claim 108 wherein the cancer treated is melanoma, gastric carcinoma, or non-small cell lung carcinoma.

30

          117. The method of Claim 109, wherein the cancer treated is melanoma, gastric carcinoma, or non-small cell lung carcinoma.



118. The method of Claim 106 wherein said disease is COPD.

119. The method of Claim 106 wherein said disease is acute inflammation.

5

120. The method of Claim 106 wherein said disease is rheumatoid arthritis.

10

121. The method of Claim 106 wherein said disease is acute inflammatory pain.

15

122. The method of Claim 106 wherein said disease is chronic inflammatory pain.

20


123. The method of Claim 106 wherein said disease is acute neuropathic pain.

25

124. The method of Claim 106 wherein said disease is chronic neuropathic pain.

30


125. A method of treating a chemokine-mediated disease, in a patient in need of such treatment, wherein the chemokine binds to a CXCR2 and/or CXCR1 receptor in said patient, comprising administering to said patient an effective amount of at least one compound of formula IA:






and the pharmaceutically acceptable salts and solvates thereof, wherein:

A is selected from the group consisting of:



(1)



5









10




15

501




5



10






(2)




5



10



15




5

wherein the above rings of said A groups are substituted with 1 to 6 substituents each independently selected from the group consisting of:  $R^9$  groups;


10

(3)




15

504



- 5 wherein one or both of the above rings of said A groups are substituted with 1 to 6 substituents each independently selected from the group consisting of:  $R^9$  groups;


(4)




10

- wherein the above phenyl rings of said A groups are substituted with 1 to 3 substituents each independently selected from the group consisting of:  $R^9$  groups; and


(5)



15



B is:



10 n is 0 to 6;

p is 1 to 5;

X is O, NH, or S;

Z is 1 to 3;

15  $\text{R}^2$  is selected from the group consisting of: hydrogen, OH,  $\text{---C(O)OH}$ ,  $\text{---SH}$ ,  
 $\text{---SO}_2\text{NR}^{13}\text{R}^{14}$ ,  $\text{---NHC(O)R}^{13}$ ,  $\text{---NH}\text{SO}_2\text{NR}^{13}\text{R}^{14}$ ,  $\text{---NH}\text{SO}_2\text{R}^{13}$ ,  $\text{---NR}^{13}\text{R}^{14}$ ,  $\text{---C(O)NR}^{13}\text{R}^{14}$ ,  
 $\text{---C(O)NHR}^{13}$ ,  $\text{---C(O)NR}^{13}\text{OH}$ ,  $\text{---S(O}_2\text{)OH}$ ,  $\text{---OC(O)R}^{13}$ , an unsubstituted heterocyclic  
 acidic functional group, and a substituted heterocyclic acidic functional group; wherein  
 there are 1 to 6 substituents on said substituted heterocyclic acidic functional group  
 each substituent being independently selected from the group consisting of:  $\text{R}^9$   
 20 groups;

each  $\text{R}^3$  and  $\text{R}^4$  is independently selected from the group consisting of:  
 hydrogen, cyano, halogen, alkyl, alkoxy,  $\text{---OH}$ ,  $\text{---CF}_3$ ,  $\text{---OCF}_3$ ,  $\text{---NO}_2$ ,  $\text{---C(O)R}^{13}$ ,  
 $\text{---C(O)OR}^{13}$ ,  $\text{---C(O)NHR}^{17}$ ,  $\text{---SO}_{(t)}\text{NR}^{13}\text{R}^{14}$ ,  $\text{---SO}_{(t)}\text{R}^{13}$ ,  $\text{---C(O)NR}^{13}\text{OR}^{14}$ , unsubstituted or

substituted aryl, unsubstituted or substituted heteroaryl; wherein there are 1 to 6 substituents on said substituted aryl group and each substituent is independently selected from the group consisting of:  $R^9$  groups; and wherein there are 1 to 6 substituents on said substituted heteroaryl group and each substituent is independently selected from the group consisting of:  $R^9$  groups;

each  $R^5$  and  $R^6$  are the same or different and are independently selected from the group consisting of hydrogen, halogen, alkyl, alkoxy,  $-CF_3$ ,  $-OCF_3$ ,  $-NO_2$ ,  $-C(O)R^{13}$ ,  $-C(O)OR^{13}$ ,  $-C(O)NR^{13}R^{14}$ ,  $-SO_{(t)}NR^{13}R^{14}$ ,  $-C(O)NR^{13}OR^{14}$ , cyano, unsubstituted or substituted aryl, and unsubstituted or substituted heteroaryl group; wherein there are 1 to 6 substituents on said substituted aryl group and each substituent is independently selected from the group consisting of:  $R^9$  groups; and wherein there are 1 to 6 substituents on said substituted heteroaryl group and each substituent is independently selected from the group consisting of:  $R^9$  groups;

each  $R^7$  and  $R^8$  is independently selected from the group consisting of: H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heteroarylalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted cycloalkylalkyl,  $-CO_2R^{13}$ ,  $-CONR^{13}R^{14}$ , alkynyl, alkenyl, and cycloalkenyl; and wherein there are one or more substituents on said substituted  $R^7$  and  $R^8$  groups, wherein each substituent is independently selected from the group consisting of:

- a) halogen,
- b)  $-CF_3$ ,
- c)  $-COR^{13}$ ,
- d)  $-OR^{13}$ ,
- e)  $-NR^{13}R^{14}$ ,
- f)  $-NO_2$ ,
- g)  $-CN$ ,
- h)  $-SO_2OR^{13}$ ,
- i)  $-Si(alkyl)_3$ , wherein each alkyl is independently selected,
- j)  $-Si(aryl)_3$ , wherein each alkyl is independently selected,
- k)  $-(R^{13})_2R^{14}Si$ , wherein each  $R^{13}$  is independently selected,
- l)  $-CO_2R^{13}$ ,
- m)  $-C(O)NR^{13}R^{14}$ ,




- n)  $-\text{SO}_2\text{NR}^{13}\text{R}^{14}$ ,  
 o)  $-\text{SO}_2\text{R}^{13}$ ,  
 p)  $-\text{OC}(\text{O})\text{R}^{13}$ ,  
 q)  $-\text{OC}(\text{O})\text{NR}^{13}\text{R}^{14}$ ,  
 5 r)  $-\text{NR}^{13}\text{C}(\text{O})\text{R}^{14}$ , and  
 s)  $-\text{NR}^{13}\text{CO}_2\text{R}^{14}$ ;

$\text{R}^{8a}$  is selected from the group consisting of: hydrogen, alkyl, cycloalkyl and cycloalkylalkyl;

each  $\text{R}^9$  is independently selected from the group consisting of:

- 10 a)  $-\text{R}^{13}$ ,  
 b) halogen,  
 c)  $-\text{CF}_3$ ,  
 d)  $-\text{COR}^{13}$ ,  
 e)  $-\text{OR}^{13}$ ,  
 15 f)  $-\text{NR}^{13}\text{R}^{14}$ ,  
 g)  $-\text{NO}_2$ ,  
 h)  $-\text{CN}$ ,  
 i)  $-\text{SO}_2\text{R}^{13}$ ,  
 j)  $-\text{SO}_2\text{NR}^{13}\text{R}^{14}$ ,  
 20 k)  $-\text{NR}^{13}\text{COR}^{14}$ ,  
 l)  $-\text{CONR}^{13}\text{R}^{14}$ ,  
 m)  $-\text{NR}^{13}\text{CO}_2\text{R}^{14}$ ,  
 n)  $-\text{CO}_2\text{R}^{13}$ ,  
 o)



- p) alkyl substituted with one or more  $-\text{OH}$  groups,  
 q) alkyl substituted with one or more  $-\text{NR}^{13}\text{R}^{14}$  group, and  
 r)  $-\text{N}(\text{R}^{13})\text{SO}_2\text{R}^{14}$ ;

$\text{R}^{12}$  is selected from the group consisting of: hydrogen,  $-\text{C}(\text{O})\text{OR}^{13}$ ,  
 30 unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or

substituted alkyl, unsubstituted or substituted cycloalkylalkyl, and unsubstituted or substituted heteroarylalkyl group; wherein there are 1 to 6 substituents on the substituted  $R^{12}$  groups and each substituent is independently selected from the group consisting of:  $R^9$  groups;

5 each  $R^{13}$  and  $R^{14}$  is independently selected from the group consisting of: H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heteroarylalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heterocyclic, unsubstituted or substituted fluoroalkyl, and unsubstituted or substituted heterocycloalkylalkyl; wherein there are 1 to 6 substituents on said substituted  $R^{13}$  and  $R^{14}$  groups and each substituent is independently selected from the group consisting of: alkyl,  $-CF_3$ ,  $-OH$ , alkoxy, aryl, arylalkyl, fluoroalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl,  $-N(R^{40})_2$ ,  $-C(O)OR^{15}$ ,  $-C(O)NR^{15}R^{16}$ ,  $-S(O)_iNR^{15}R^{16}$ ,  $-C(O)R^{15}$ ,  $-SO_2R^{15}$  provided that 15  $R^{15}$  is not H, halogen, and  $-NHC(O)NR^{15}R^{16}$ ; or

$R^{13}$  and  $R^{14}$  taken together with the nitrogen they are attached to in the groups  $-NR^{13}R^{14}$ ,  $-C(O)NR^{13}R^{14}$ ,  $-SO_2NR^{13}R^{14}$ ,  $-OC(O)NR^{13}R^{14}$ ,  $-CONR^{13}R^{14}$ ,  $-NR^{13}C(O)NR^{13}R^{14}$ ,  $-SO_iNR^{13}R^{14}$ ,  $-NHSO_2NR^{13}R^{14}$  form an unsubstituted or substituted saturated heterocyclic ring, said ring optionally containing one additional 20 heteroatom selected from the group consisting of: O, S and  $NR^{18}$ ; wherein there are 1 to 3 substituents on the substituted cyclized  $R^{13}$  and  $R^{14}$  groups and each substituent is independently selected from the group consisting of: alkyl, aryl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, arylalkyl, fluoroalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, amino,  $-C(O)OR^{15}$ ,  $-C(O)NR^{15}R^{16}$ ,  $-SO_iNR^{15}R^{16}$ ,  $-C(O)R^{15}$ , 25  $-SO_2R^{15}$  provided that  $R^{15}$  is not H,  $-NHC(O)NR^{15}R^{16}$ ,  $-NHC(O)OR^{15}$ , halogen, and a heterocycloalkenyl group;

each  $R^{15}$  and  $R^{16}$  is independently selected from the group consisting of: H, alkyl, aryl, arylalkyl, cycloalkyl and heteroaryl;

$R^{17}$  is selected from the group consisting of:  $-SO_2$ alkyl,  $-SO_2$ aryl, 30  $-SO_2$ cycloalkyl, and  $-SO_2$ heteroaryl;

$R^{18}$  is selected from the group consisting of: H, alkyl, aryl, heteroaryl,  $-C(O)R^{19}$ ,  $-SO_2R^{19}$  and  $-C(O)NR^{19}R^{20}$ ;

each R<sup>19</sup> and R<sup>20</sup> is independently selected from the group consisting of: alkyl, aryl and heteroaryl;

each R<sup>40</sup> is independently selected from the group consisting of: H, alkyl and cycloalkyl; and

5 t is 0, 1 or 2.

126. The method of Claim 125 wherein the chemokine mediated disease is selected from the group consisting of: acute inflammatory pain, chronic inflammatory  
 10 pain, acute neuropathic pain, chronic neuropathic pain, acute inflammation, rheumatoid arthritis, psoriasis, atopic dermatitis, asthma, COPD, adult respiratory disease, arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, stroke, cardiac and renal reperfusion injury, glomerulonephritis, thrombosis, Alzheimer's  
 15 disease, graft vs. host reaction, allograft rejections, malaria, acute respiratory distress syndrome, delayed type hypersensitivity reaction, atherosclerosis, cerebral and cardiac ischemia, osteoarthritis, multiple sclerosis, restinosis, angiogenesis, osteoporosis, gingivitis, respiratory viruses, herpes viruses, hepatitis viruses, HIV, Kaposi's sarcoma associated virus, meningitis, cystic fibrosis, pre-term labor, cough,  
 20 pruritis, multi-organ dysfunction, trauma, strains, sprains, contusions, psoriatic arthritis, herpes, encephalitis, CNS vasculitis, traumatic brain injury, CNS tumors, subarachnoid hemorrhage, post surgical trauma, interstitial pneumonitis, hypersensitivity, crystal induced arthritis, acute and chronic pancreatitis, acute alcoholic hepatitis, necrotizing enterocolitis, chronic sinusitis, angiogenic ocular  
 25 disease, ocular inflammation, retinopathy of prematurity, diabetic retinopathy, macular degeneration with the wet type preferred and corneal neovascularization, polymyositis, vasculitis, acne, gastric and duodenal ulcers, celiac disease, esophagitis, glossitis, airflow obstruction, airway hyperresponsiveness, bronchiectasis, bronchiolitis, bronchiolitis obliterans, chronic bronchitis, cor pulmonae, cough,  
 30 dyspnea, emphysema, hypercapnea, hyperinflation, hypoxemia, hyperoxia-induced inflammations, hypoxia, surgical lung volume reduction, pulmonary fibrosis, pulmonary hypertension, right ventricular hypertrophy, peritonitis associated with continuous ambulatory peritoneal dialysis (CAPD), granulocytic ehrlichiosis, sarcoidosis, small

airway disease, ventilation-perfusion mismatching, wheeze, colds, gout, alcoholic liver disease, lupus, burn therapy, periodontitis, transplant reperfusion injury and early transplantation rejection, and chronic inflammation.

5

127. The method of Claim 125 wherein said chemokine-mediated disease is cancer.

10

128. The method of Claim 127 wherein the compound of formula IA is administered in combination with the administration of at least one anticancer agent.

15

129. The method of Claim 128 wherein said anticancer agent is selected from the group consisting of: alkylating agents, antimetabolites, natural products and their derivatives, hormones, anti-hormones, anti-angiogenic agents and steroids, and synthetics.

20

130. The method of Claim 125 wherein angiogenesis is inhibited.

25

131. The method of Claim 130 wherein the compound of formula IA is administered in combination with the administration of an effective amount of at least one anti-angiogenesis compound.

30

132. The method of Claim 125 wherein said chemokine-mediated disease is selected from the group consisting of: gingivitis, respiratory viruses, herpes viruses, hepatitis viruses, HIV, kaposi's sarcoma associated virus and atherosclerosis.

133. The method of Claim 125 wherein the chemokine mediated disease is an angiogenic ocular disease.

5           134. The method of Claim 133 wherein said angiogenic ocular disease is selected from the group consisting of: ocular inflammation, retinopathy of prematurity, diabetic retinopathy, macular degeneration with the wet type preferred and corneal neovascularization.

10           135. The method of Claim 127 wherein the cancer treated is melanoma, gastric carcinoma, or non-small cell lung carcinoma.


15           136. The method of Claim 128 wherein the cancer treated is melanoma, gastric carcinoma, or non-small cell lung carcinoma.

20           137. The method of Claim 129, wherein the cancer treated is melanoma, gastric carcinoma, or non-small cell lung carcinoma.

          138. The method of Claim 106 wherein said disease is chronic inflammation.

25           139. The method of Claim 125 wherein said disease is COPD, acute inflammation, chronic inflammation, rheumatoid arthritis, acute inflammatory pain, chronic inflammatory pain, acute neuropathic pain, chronic neuropathic pain.

140. The method of Claim 106 wherein said compound is:



141. The method of Claim 140 wherein said disease is selected from the group consisting of: COPD, rheumatoid arthritis, acute inflammation, chronic inflammation, acute inflammatory pain, chronic inflammatory pain, acute neuropathic pain, and chronic neuropathic pain.


142. The method of Claim 141 wherein said disease is COPD.

143. The method of Claim 141 wherein said disease is rheumatoid arthritis.

144. The method of Claim 141 wherein said disease is acute inflammation or chronic inflammation.

145. The method of Claim 141 wherein said disease is selected from the group consisting of: acute inflammatory pain, chronic inflammatory pain, acute neuropathic pain and chronic neuropathic pain.

146. The method of Claim 106 wherein said compound is:



147. The method of Claim 146 wherein said disease is selected from the group consisting of: COPD, rheumatoid arthritis, acute inflammation, chronic inflammation, acute inflammatory pain, chronic inflammatory pain, acute neuropathic pain, and chronic neuropathic pain.


148. The method of Claim 146 wherein said disease is COPD.

149. The method of Claim 146 wherein said disease is rheumatoid arthritis.

150. The method of Claim 146 wherein said disease is acute inflammation or chronic inflammation.

151. The method of Claim 146 wherein said disease is selected from the group consisting of: acute inflammatory pain, chronic inflammatory pain, acute neuropathic pain and chronic neuropathic pain.

152. The method of Claim 106 wherein said compound is:



153. The method of Claim 152 wherein said disease is selected from the group consisting of: COPD, rheumatoid arthritis, acute inflammation, chronic inflammation, acute inflammatory pain, chronic inflammatory pain, acute neuropathic pain, and chronic neuropathic pain.

154. The method of Claim 152 wherein said disease is COPD.

155. The method of Claim 152 wherein said disease is rheumatoid arthritis.

156. The method of Claim 152 wherein said disease is acute inflammation or chronic inflammation.

157. The method of Claim 152 wherein said disease is selected from the group consisting of: acute inflammatory pain, chronic inflammatory pain, acute neuropathic pain and chronic neuropathic pain.